# Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

> **NCT00324740** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Recurrent Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** isotretinoin

## Key facts

- **NCT ID:** NCT00324740
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2011-02
- **Final completion:** 2014-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324740, "Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00324740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*